Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche : Canadian Blood Services selects Roche Diagnostics Canada as a partner of choice for blood screening in Canada

09/23/2021 | 08:58am EDT
  • Canadian Blood Services will be the first site in North America implementing Roche's Serology and Donor Screening solutions
  • Serology testing will use Roche's cobas® 8000 Systems with cobas e801 modules to screen all donations for Anti-HBc II, HBsAg II, Anti-HCV II, HIV Duo, HTLV I/II and Chagas
  • This partnership positions Roche Diagnostics Canada as a leader in serology testing for infectious diseases and in donor screening testing in Canada
  • This project also augments the existing infectious diseases and microbiology innovation work done at Canadian Blood Services.

LAVAL, QC, Sept. 23, 2021/CNW Telbec/ - Roche Diagnostics, a division of Hoffmann-La Roche Limited, is proud to announce a new partnership with Canadian Blood Services to support blood screening in Canada. Blood donations will be tested using Roche Blood Safety Solutions where Pre-analytics, Nucleic Acid Testing and Serology Systems will work in synergy. In addition, the use of Roche's cobas e-flow will bring greater efficiency to Canadian Blood Services' workflow.

"We are thrilled by Canadian Blood Services' decision to trust our innovative solutions to ensure high quality testing and continue to provide lifesaving products and services for patients in Canada", said Andrew Plank, President and General Manager at Roche Diagnostics Canada. "We know blood transfusions and plasma-derived therapeutics have the power to save lives every day and choosing Roche as a partner means working with an organization whose state-of-the-art solutions are being successfully used all over the world. This partnership fits perfectly with our purpose: Doing now what patients need next."

Canadian Blood Services tests approximately 820,000 blood donations per year and represents 80% of the blood donated in Canada. Its focus is on life essentials for transfusion and transplantation, including blood, plasma, stem cells, and organs and tissues. 

"This project makes Canadian Blood Services the first blood operator in North America to implement Roche serology assays for donor screening and enhances our ongoing work to innovate in the areas of infectious diseases and microbiology", said Dr. Steven Drews, Associate Director - Microbiology at Canadian Blood Services.

Roche and Canadian Blood Services: A long-standing partnership

Roche and Canadian Blood Services have worked together for over 20 years to bring innovation in blood screening methods. In 2017, the blood operator implemented Roche's cobas® 8800 Systems with pre-analytics that improves staffing efficiency and offers flexibility to meet changing needs and productivity improvement. Canadian Blood Services and Roche are partners committed to best patient safety and best patient care.

In 2021, Canadian Blood Services continues to use Roche assays to generate information on SARS-CoV-2 that informs public health decisions and further innovation work.

Roche Diagnostics Canada partnered with Canadian Blood Services to support a seroprevalence study in Canada, which includes the use of Roche's Elecsys® Anti-SARS-CoV-2-S and Elecsys® Anti-SARS-CoV-2 serology tests, aiming to better understand the immune response to SARS-CoV-2 by comparing the level of antibodies generated by COVID-19 vaccines and natural infection.

About Canadian Blood Services

Canadian Blood Services is a not-for-profit charitable organization. Regulated by Health Canada as a biologics manufacturer and primarily funded by the provincial and territorial ministries of health, Canadian Blood Services operates with a national scope, infrastructure and governance that make it unique within Canadian healthcare. In the domain of blood, plasma, and stem cells, Canadian Blood Services provides products and services to hospitals on behalf of all provincial and territorial governments, except Quebec. The national transplant registry for interprovincial organ sharing and related programs reaches into all provinces and territories, as a biological lifeline for Canadians. For more information visit: blood.ca

About Roche Blood Safety Solutions

Roche has been dedicated to blood screening since 1998. The company has a strong heritage in infectious diseases and the assays offered for blood screening exploit innovative technologies specifically developed for serology and nucleic acid testing (NAT) platforms.

Roche is the only provider of a complete state-of-the-art donor screening solution that integrates NATs, serology solutions, and lab automation and software solutions. This integration allows laboratories worldwide to experience the simplicity of leveraging a one-provider solution that increases workflow efficiencies and reduces the risk of manual handling errors, more consistent results, and ultimately more control over the laboratory's process. Roche systems are designed to improve workflow efficiencies, providing modular and automated solutions for labs of all sizes.

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in data-driven medical insights, help Roche deliver truly personalized healthcare. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche Canada was founded in 1931 and employs more than 1,800 people across the country through its Pharmaceuticals division in Mississauga, Ontario as well as its Diagnostics and Diabetes Care divisions in Laval, Quebec.

For more information, please visit www.RocheCanada.com and diagnostics.roche.com or follow us on Twitter @RocheCanada.

All trademarks used or mentioned in this release are protected by law.

 

SOURCE Roche Diagnostics Canada

© Canada Newswire, source Canada Newswire English

All news about ROCHE HOLDING AG
09:25aROCHE : Atea Pharmaceuticals COVID-19 Drug Fails To Meet Phase Two Endpoint
MT
07:44aAtea plunges after COVID-19 treatment fails to help patients in study
RE
06:41aAtea Shares Fall 75% After Covid-19 Trial Misses Objective
DJ
05:51aAtea's Covid-19 Trial Misses Objective in Overall Patient Population
DJ
10/18GLOBAL MARKETS LIVE : Valneva, Glencore, Facebook, Roche, Hertz...
10/18Today on Wall Street: This is the real test
10/18Roche Announces Collaboration with Ibex Medical Analytics to Develop Artificial Intelli..
CI
10/17ROCHE : Heirs to Shut Down Philanthropic Foundation Focused on Nature Conservation
MT
10/17ROCHE : Wins US FDA Nod For Non-Small Cell Lung Cancer Therapy Tecentriq
MT
10/17ROCHE : family shareholders will maintain stability - vice chairman
RE
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2021 61 829 M 67 202 M 67 202 M
Net income 2021 14 572 M 15 839 M 15 839 M
Net cash 2021 4 469 M 4 858 M 4 858 M
P/E ratio 2021 21,2x
Yield 2021 2,58%
Capitalization 316 B 343 B 344 B
EV / Sales 2021 5,05x
EV / Sales 2022 4,90x
Nbr of Employees 101 465
Free-Float 83,5%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | ROG | CH0012032048 | MarketScreener
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 363,95 CHF
Average target price 382,53 CHF
Spread / Average Target 5,11%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG15.42%342 644
JOHNSON & JOHNSON1.74%421 513
NOVO NORDISK A/S56.38%238 110
PFIZER, INC.12.71%231 668
ELI LILLY AND COMPANY41.54%216 655
MERCK & CO., INC.-5.68%195 296